BeOne Medicines (ONC) Interest Expenses (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Interest Expenses data on file, last reported at $32.9 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 153.74% year-over-year to $32.9 million in Q1 2026; TTM through Mar 2026 was $69.9 million, a 23.54% increase from a year earlier, with the FY2025 full-year figure at $3.6 billion, up 7.18% from the prior year.
• Interest Expenses for Q1 2026 stood at $32.9 million, up from $12.3 million in the prior quarter.
• Over the last five years, Interest Expenses for ONC reached as high as $32.9 million in Q1 2026 and fell as low as -$11.7 million in Q4 2023.
• Historically, Interest Expenses has averaged $10.2 million across 5 years, with a median of $12.0 million in 2025.
• Across the five-year window, Interest Expenses sank 202.15% in 2023 and soared 236.87% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $11.5 million in 2022, then sank by 202.15% to -$11.7 million in 2023, then surged by 236.87% to $16.1 million in 2024, then retreated by 23.45% to $12.3 million in 2025, then jumped by 167.57% to $32.9 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $32.9 million in Q1 2026, $12.3 million in Q4 2025, and $12.6 million in Q3 2025.